164 related articles for article (PubMed ID: 1539506)
1. Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis.
Rebuzzi AG; Natale A; Bianchi C; Albanese S; Lanza GA; Coppola E; Ciabattoni G
Am Heart J; 1992 Mar; 123(3):560-6. PubMed ID: 1539506
[TBL] [Abstract][Full Text] [Related]
2. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator.
Kerins DM; Roy L; FitzGerald GA; Fitzgerald DJ
Circulation; 1989 Dec; 80(6):1718-25. PubMed ID: 2513144
[TBL] [Abstract][Full Text] [Related]
3. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.
Fitzgerald DJ; Catella F; Roy L; FitzGerald GA
Circulation; 1988 Jan; 77(1):142-50. PubMed ID: 3275505
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction.
DeFilippis AP; Oloyede OS; Andrikopoulou E; Saenger AK; Palachuvattil JM; Fasoro YA; Guallar E; Blumenthal RS; Kickler TS; Jaffe AS; Gerstenblith G; Schulman SP; Rade JJ
Circ J; 2013; 77(11):2786-92. PubMed ID: 23985963
[TBL] [Abstract][Full Text] [Related]
5. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
[TBL] [Abstract][Full Text] [Related]
6. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.
Fitzgerald DJ; Wright F; FitzGerald GA
Circ Res; 1989 Jul; 65(1):83-94. PubMed ID: 2500270
[TBL] [Abstract][Full Text] [Related]
7. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
8. Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction.
Rasmanis G; Vesterqvist O; Gréen K; Edhag O; Henriksson P
Br Heart J; 1992 Oct; 68(4):374-6. PubMed ID: 1449919
[TBL] [Abstract][Full Text] [Related]
9. [Platelet activation in the early phases of acute myocardial infarction].
Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
[TBL] [Abstract][Full Text] [Related]
10. Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction.
Uyama O; Shimizu S; Nakanishi T; Nakahama H; Takiguchi A; Hayashi Y; Yamamoto S; Sugita M
Intern Med; 1992 Jun; 31(6):735-9. PubMed ID: 1392173
[TBL] [Abstract][Full Text] [Related]
11. Increased thromboxane metabolites excretion in liver cirrhosis.
Davì G; Ferro D; Basili S; Iuliano L; Camastra C; Giammarresi C; Santarone S; Rocca B; Landolfi R; Ciabattoni G; Cordova C; Violi F
Thromb Haemost; 1998 Apr; 79(4):747-51. PubMed ID: 9569186
[TBL] [Abstract][Full Text] [Related]
12. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.
Moser M; Nordt T; Peter K; Ruef J; Kohler B; Schmittner M; Smalling R; Kübler W; Bode C
Circulation; 1999 Nov; 100(18):1858-64. PubMed ID: 10545429
[TBL] [Abstract][Full Text] [Related]
13. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
14. Increased thromboxane biosynthesis in essential thrombocythemia.
Rocca B; Ciabattoni G; Tartaglione R; Cortelazzo S; Barbui T; Patrono C; Landolfi R
Thromb Haemost; 1995 Nov; 74(5):1225-30. PubMed ID: 8607099
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
Circulation; 1994 Feb; 89(2):588-95. PubMed ID: 8313547
[TBL] [Abstract][Full Text] [Related]
16. Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey.
Patrignani P; Morton H; Cirino M; Lord A; Charette L; Gillard J; Rokach J; Patrono C
Biochim Biophys Acta; 1989 Jul; 992(1):71-7. PubMed ID: 2752041
[TBL] [Abstract][Full Text] [Related]
17. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
[TBL] [Abstract][Full Text] [Related]
18. Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor.
Ikonomidis I; Andreotti F; Nihoyannopoulos P
Heart; 2004 Apr; 90(4):389-93. PubMed ID: 15020512
[TBL] [Abstract][Full Text] [Related]
19. Thromboxane A2 synthesis in pregnancy-induced hypertension.
Fitzgerald DJ; Rocki W; Murray R; Mayo G; FitzGerald GA
Lancet; 1990 Mar; 335(8692):751-4. PubMed ID: 1969511
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the fibrinolytic system components during acute myocardial infarction.
Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
